THE LITTLE ENGINE THAT COULDThis is a very appropriate American folk tale and fits where we are now. Neil Cashman has worked decades on a computational algorithm to identify what neurological diseases are caused by misfolded proteins and how to identify them. Now he has developed this and devised a way to create antibodies specific to the toxicity of the protein. Big pharma consitantly gives him a deaf ear and that with plaqued with poor management gives him an even further insurmountable task. Goldstein and Williams have destroyed the share structure and theit years of lies have placed us in a begging situation. Now with the 1B dosing about to commence, if and I do mean if Neil can show any efficacy without any Edema, we will hit a home run. Remember this, you do not have to wait till the end of 1B to see results, as they are dosing once a month and doing all the scans regularly. My guess would be that big pharma has NDA'S signed with Promis and that they will monitor this closely as data is recorded. Will be an interesting few months ahead for sure. Now we need to dump Williams off this board and save paying for his inept input.